Atea Pharmaceuticals, Inc. Federal Income Tax Expense (Benefit), Continuing Operations
Atea Pharmaceuticals, Inc. (AVIR) reported Federal Income Tax Expense (Benefit), Continuing Operations of -$6.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-03-05
- Atea Pharmaceuticals, Inc. federal income tax expense (benefit), continuing operations for the quarter ending 2022-03-31 was $0.00.
- Atea Pharmaceuticals, Inc. federal income tax expense (benefit), continuing operations for the quarter ending 2021-03-31 was $0.00.
- Atea Pharmaceuticals, Inc. federal income tax expense (benefit), continuing operations for fiscal 2025 was -$6.21M, a 1112.56% decline from fiscal 2024.
- Atea Pharmaceuticals, Inc. federal income tax expense (benefit), continuing operations for fiscal 2024 was $613.00K.
| Period end | Federal Income Tax Expense (Benefit), Continuing Operations 3 month | Federal Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|---|
| 2025-12-31 | -$6.21M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $613.00K 10-K · filed 2026-03-05 | |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-10 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |